




## Pricing tool: reimbursement price trends

- Package and reimbursement prices over time
- **NEW:** mean annual therapy costs before and after reimbursement price negotiations, weighted by patient share
- **NEW:** premium over the appropriate comparative treatment including consideration of watchful waiting, physician's choice and Best Supportive Care



## Upon request: Prediction Tool for additional benefit assessment

- Prediction of the extent and probability of an additional benefit in the AMNOG procedure after Phase I/II
- Algorithm-based machine-learning program based on more than 3 million individual data points and over 650 G-BA resolutions
- Text analysis with the help of Natural Language Processing (NLP)
- Forecast based on accuracy, mode of action, marketing authorisation, study design, comparator, endpoints and effect sizes
- Optimum planning for joint scientific advice (BfArM/G-BA) before the start of the pivotal phase III trials



Institut für Pharmakologie  
und präventive Medizin  
Dr. Johannes Hankowitz  
Dr. Bramlage & Dr. Hankowitz Partnerschaft

Contact us: Dr. Johannes Hankowitz · Adelsbergstraße 23, 81247 München  
Phone: +49 170-3 09 55 91 · E-Mail: hankowitz@ippmed.de · www.amnog-monitor.com



Interactive online analysis tool  
[www.amnog-monitor.com](http://www.amnog-monitor.com)

# AMNOG-MONITOR

Early benefit assessment analysis: Information · Analysis · Research

# AMNOG-MONITOR



## Overview of early benefit assessments and the outcome of price negotiations

- Up-to-date analyses of all G-BA early benefit assessment resolutions
- Price trends for all assessed medicinal products
- Essential for Market Access, Pricing & Reimbursement, F&E, Business Development and Legal Affairs
- Additional index-based full-text search in all IQWiG assessments, G-BA resolutions and justifications, commenting procedures etc.
- Bilingual (English and German)

## Information on all G-BA resolutions

- Monthly overview of the G-BA's decision-making practice
- Structured individual analyses of every G-BA resolution (over 650 decisions) plus lessons learnt for each case
- Management presentation on the current status of early benefit assessment (English-language PPT presentation)
- Evaluations by indication area
- Comparison of all decisions: pharmaceutical company's claims, IQWiG assessment and G-BA resolution incl. weighting by patient numbers
- Data from the AIS information system for physicians, such as endpoint assessment
- **NEW:** ICD-10-Codes
- All files available for download as PDFs
- **NEW:** All graphics exportable

The table lists endpoints and compares them across different methods. It includes columns for 'Therapieoption', 'Endpunkte', 'PUI-Dimension', 'G-BA Bewertung', and 'Arztinformationssystem (AIS)'. The table is divided into sections for '77% Anhaltspunkt für beträchtlichen Zusatznutzen' and '23% Hinweis auf beträchtlichen Zusatznutzen'.

The pivot table shows 'Grund des Verfahrens' on the y-axis and 'Tabelle' on the x-axis. The rows list various decision types such as 'Zulassung', 'Erlaubnis', 'Widerruf', and 'Einstufung'.

## Analysis tool: interactive evaluation of all G-BA resolutions

- Pivot table with all G-BA resolutions
- Pivot table with all subpopulations
- Evaluations by reason for procedure, additional benefit, type of marketing authorisation, endpoints, arbitration decisions, withdrawals, changes in appropriate comparative therapy, price rebates and much more
- **NEW:** Automatic Excel-Export with links to respective resolutions
- Evaluation options by appropriate comparative treatment, control group APIs, submitted endpoints, average annual therapy costs
- **NEW:** Saving, loading and automatic updates of individual table configurations ("bookmarks")